Table 4.
Active combinatorial trials in prostate cancer.
| Trial ID | Cancer | PARP inhibitor | Immunotherapy | Phase |
|---|---|---|---|---|
| NCT02484404 | Metastatic CRPC | Olaparib | Atezolizumab (PD-L1) cediranib (VEGFR) | I/II |
| NCT02660034 | Metastatic CRPC | BGB-290 | BGB-A317 (PD-1) | I/II |
| NCT02861573 | Metastatic CRPC | Olaparib | Pembrolizumab (PD-1) | I/II |
| NCT03572478 | Metastatic CRPC | Rucaparib | Nivolumab (PD-1) | I/II |
| NCT03330405 | CRPC | Talazoparib | Avelumab (PD-1) | II |
| NCT03338790 | CRPC | Rucaparib | Nivolumab (PD-1) | II |
| NCT03834519 | Metastatic CRPC | Olaparib | Pembrolizumab (PD-1) | III |
CRPC, Castration-resistant prostate cancer.